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Does modulation of the endocannabinoid system have
potential therapeutic utility in cerebellar ataxia?
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Abstract Cerebellar ataxias represent a spectrum of disorders which are, however, linked by
common symptoms of motor incoordination and typically associated with deficiency in Purkinje
cell firing activity and, often, degeneration. Cerebellar ataxias currently lack a curative agent. The
endocannabinoid (eCB) system includes eCBcompounds and their associatedmetabolic enzymes,
together with cannabinoid receptors, predominantly the cannabinoid CB1 receptor (CB1R) in
the cerebellum; activation of this system in the cerebellar cortex is associated with deficits in
motor coordination characteristic of ataxia, effects which can be prevented by CB1R antagonists.
Gary Stephens held postdoctoral and Fellowship positions with Wyeth Research, Imperial College and University
College London before moving to University of Reading in 2005, where he is now Professor of Pharmacology and
Director of Pharmacology and Therapeutics. His research interests are in the modulation of presynaptic calcium
channels and G protein-coupled receptors, with a particular interest in cerebellar function.
This reviewwaspresented at the symposium“Mechanismsof cerebellar ataxias andneurodegeneration”,which tookplace atAgeing andDegeneration:
A Physiological Perspective in Edinburgh, UK, 10–11 April 2015.
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Of further interest are various findings that CB1R deficits may also induce a progressive ataxic
phenotype. Together these studies suggest that motor coordination is reliant on maintaining the
correct balance in eCB system signalling. Recent work also demonstrates deficient cannabinoid
signalling in themouse ‘ducky2J’model of ataxia. In light of these points, the potentialmechanisms
whereby cannabinoids may modulate the eCB system to ameliorate dysfunction associated with
cerebellar ataxias are considered.
(Received 14 June 2015; accepted after revision 4 February 2016; first published online 11 March 2016)
Corresponding authors G. J. Stephens: School of Pharmacy, University of Reading, Whiteknights, Reading RG6 6AJ,
UK. Email: g.j.stephens@reading.ac.uk
Abstract figure legend Presynaptic CB1Rs modulate Purkinje cell output in the cerebellar cortex. Interneurons (INs)
make inhibitory contacts predominantly at the so-called pinceau region surrounding the Purkinje cell (PC) soma and
also potentially at dendritic shafts. Parallel fibres (PFs) arise from granule cells, which in turn receive input from mossy
fibres, and make weak but numerous excitatory contacts predominantly with postsynaptic dendritic spines. Climbing
fibres (CFs) arise from the inferior olive andmake strongmonosynaptic contactswith individual PCswithin the dendritic
tree, predominantly at dendritic shafts. 2-Arachidonylglycerol (2-AG), the predominant endocannabinoid (eCB) in the
cerebellar cortex, is synthesized from diacylglycerol (DAG) by diacylglycerol lipase α (DAGLα); this process is driven
by activation of metabotropic receptors including mGluR1 and may also involve Ca+-dependent processes including
voltage-dependent Ca2+ channels such as CaV2.1 and also Ca2+ permeable ionotropic receptors (see Kano et al. 2009).
2-AG is released retrogradely ‘on-demand’ to active presynaptic CB1Rs. 2-AG action is terminated by monoacylglycerol
lipase (MAGL) localized predominantly to PF terminals. CB1Rs are highly expression at IN inputs into Purkinje cells
at the pinceau. CB1Rs are highly expressed at perisynaptic regions and also at extrasynaptic and synaptic PF sites, but
at lower density on CF terminals. At all presynaptic terminals, CB1Rs predominantly couple to Gαi/o to inhibit CaV2.1
Ca2+ channels via release of Gβγ subunits (shown only at IN–PC synapses for clarity). Activation of presynaptic CB1Rs
inhibits GABA release onto postsynaptic GABAA receptors and glutamate release predominantly onto postsynaptic
AMPA receptors, respectively. As PCs represent the sole output of the cerebellar cortex, CB1Rs are ideally localized to
control cerebellar function.
Abbreviations 2-AG, 2-arachidonylglycerol; CBD, cannabidiol; CBDV, cannabidivarin; CF, climbing fibre; eCB,
endocannabinoid; GPCR, G protein-coupled receptor; IN, interneuron; LTD, long term depression; MAGL, mono-
acylglycerol lipase; PC, Purkinje cell; pCB, phytocannabinoid; PF, parallel fibre; SCA, spinocerebellar ataxia; 9-THC,
tetrahydrocannabinol; VDCC, voltage-dependent Ca2+ channel.
Cerebellar ataxias are a diverse group of disorders
lacking a therapeutic agent
Cerebellar ataxias comprise a group of progressive
neurological diseases associated with deficits in motor
coordination and are typically associatedwith dysfunction
and/or degeneration of Purkinje cells (PCs), the sole
efferent output of the cerebellar cortex. There are
a range of acquired ataxias and different hereditary
forms of the disease (Klockgether, 2011). Thus, ataxia
can be acquired from, amongst others, traumatic head
injury, bacterial infection (meningitis or encephalitis),
viral infection (chickenpox or measles), disruption
of blood flow (stroke or transient ischaemic attack,
haemorrhage), CNS disease (cerebral palsy or multiple
sclerosis), sustained long-term alcohol misuse, under-
active thyroid gland and cancer autoimmune conditions
(lupus), and can also be iatrogenic. Hereditary ataxias
may be autosomal-dominant diseases, including forms
of spinocerebellar ataxia (SCA), several of which are
associatedwithpolyglutamine repeats in the dysfunctional
protein; for example: ataxin 1 in SCA1; ataxin 2 in SCA2;
Cacna1a encoding the voltage-dependent Ca2+ channel
(VDCC) CaV2.1 subunit in SCA6 (also in episodic ataxia
2). There are also autosomal-recessive diseases such as
Friedreich’s ataxia and ataxia telangiectasia associated
with deficits in, respectively, the mitochondrial protein
frataxin and a serine/threonine protein kinase termed
ataxia telangiectasia mutated protein (Klockgether, 2011).
Despite this range of causes and implicated proteins,
deleterious effects are largely limited to the cerebellar
cortex and are typically associated with cerebellar
dysfunction and/or degeneration and are manifest as
motor incoordination. This commonality of symptoms
offers hope for providing treatment options; however,
at present there is no known cure for cerebellar ataxia.
There are treatments to ameliorate associated symptoms.
For example, vitamin E and anti-oxidants, such as
co-enzyme Q10 and its synthetic analogue idebenone,
have been suggested to have some benefit, largely in
Friedreich ataxia. However, as yet, such agents lack
proven efficacy in controlled clinical trials (Cooper et al.
2008; Lynch et al. 2010), although some improvement
in comparison to controls was seen in cross-over trials,
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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suggesting that patients with vitamin E-deficient and
co-enzyme Q10-deficient ataxia may receive some benefit
(Cooper et al. 2008). In addition, administration of
thyrotropin-releasing hormone (TRH) was reported to
ameliorate cerebellar ataxia in rolling Nagoya mice
(Shibusawa et al. 2008) and the TRH analogue taltirelin is
approved to improvemotor performance in ataxic patients
in Japan.
The elucidation of function of proteins associated
with inherited ataxias within the cerebellar cortex may
also lead to future therapeutic advances relevant across
different forms of ataxia. Amongst target proteins, the
CaV2.1 (α1A) VDCC represents a widely studied protein.
CaV2.1 subunits are highly expressed in the cerebellum
(Westenbroek et al. 1995; Kulik et al. 2004). In particular,
CaV2.1 is expressed postsynaptically in PCs (which led
to the designation of these subunits as carriers of P-type
Ca2+ current (Mintz et al. 1992)), at presynaptic terminals
of inhibitory interneurons (INs) arising from basket
and stellate cells, and of excitatory, parallel fibres (PFs)
and climbing fibres (CFs); such inputs regulate PC,
and thus cerebellar cortex, output activity (Regehr &
Mintz, 1994; Mintz et al. 1995; Stephens et al. 2001;
Lonchamp et al. 2009). Several mouse CaV2.1 mutants
display ataxia (Pietrobon, 2010; Rajakulendran et al.
2012). Correspondingly, genetic deletion of CaV2.1 is
associated with a clear ataxic behavioural phenotype (Jun
et al. 1999). Moreover, conditional PC-specific CaV2.1
knock-downwas shown tobe sufficient to induce impaired
synaptic transmission and ataxia (Mark et al. 2011;
Todorov et al. 2012), the former study termed their mice
‘purky’. Cell-specific work was extended to excitatory
inputs into PCs, where it was shown that selective CaV2.1
knockdown in PFs (arising from mossy fibre inputs)
in so-called ‘quirky’ mice, also gave rise to an ataxic
phenotype (Maejima et al. 2013). Of further interest
here, is that mutations which increase CaV2.1 current
also give impaired synaptic transmission and irregular PC
firing (a cerebellar epitome predicted to lead to motor
incoordination) (Gao et al. 2012); these reports suggest
that correct VDCC activity must be maintained for PC
firing fidelity. To add to purky and quirky, we also have
‘ducky’ mice (Barclay et al. 2001). Ducky, and the related
ducky2J (du2J) strain, have mutations predicted to lead
to deficits in α2δ-2 auxiliary VDCC subunit protein,
which is expressed at high levels in normal cerebella
(Cole et al. 2005) and is associated predominantly with
CaV2.1 in the cerebellum (Barclay et al. 2001). In different
ducky strains, the ataxic phenotype is associated with a
reduction in postsynaptic PC whole-cell Ca2+ current
(Brodbeck et al. 2002; Donato et al. 2006), together
with irregular PC firing (Donato et al. 2006; Walter
et al. 2006; Wang et al. 2013). Thus, several potential
therapeutic targets have been suggested, largely confined
to protein associated with inherited ataxias; however, as
discussed above, as yet we have no cure for ataxia. The
remainder of this review will focus on the potential to
target the endocannabinoid (eCB) system to ameliorate
cerebellar ataxia and, in particular, eCB compounds and
their associatedmetabolic enzymes andGprotein-coupled
CB1R, one of the most ubiquitously expressed proteins
in the mammalian cerebellum, and a protein which also
modulates CaV2.1 activity at the presynapse.
Cannabinoid signalling and its potential links
to cerebellar ataxia
Cannabinoids represent a diverse number of compounds,
including (i) eCBs, for example, the lipid mediator
2-arachidonylglycerol (2-AG), which is the major eCB
in the cerebellum (Szabo et al. 2006); (ii) plant-derived
phytocannabinoids (pCBs), for example, themajor herbal
Cannabis constituents tetrahydrocannabinol (9-THC)
and cannabidiol (CBD) (Hill et al. 2012a); and (iii)
exogenous synthetic agents, namely CB1R agonists,
for example, WIN 55,212-2, an aminoalkylindole
derivative, and CP 55940, which is structurally related
to tetrahydrocannabinol, and CB1R antagonists/inverse
agonists, for example, rimonabant (Pertwee et al. 2010),
and newer allosteric modulators, for example, Org27569
(Price et al. 2005) and PSNCBAM-1 (Horswill et al. 2007).
Within the CNS, cannabinoids predominantly activate
CB1Rs, which represent the most widespread G
protein-coupled receptor (GPCR) in the mammalian
cerebellum (Herkenham et al. 1991; Tsou et al. 1997).
CB1R expression is reported to be very low at PC cell
bodies; rather, expression is high at excitatory PF inputs
into PCs, reportedlywith a perisynaptic over extrasynaptic
and synaptic localization, with lower CB1R expression
at CF inputs onto PC dendritic shafts (Kawamura et al.
2006; see Abstract Figure). CB1Rs are expressed at higher
levels on presynaptic terminals of inhibitory INs, pre-
dominantly basket cells, but also stellate cells, which
form a specialized region surrounding the PC axon initial
segment known as the pinceau (the French word for
paintbrush) (Tsou et al. 1997; Kawamura et al. 2006;
Rodrı´guez-Cueto et al. 2014). Presynaptic CB1Rs are
activated by retrograde ‘on demand’ release of 2-AG
from postsynaptic PCs. The major effect of presynaptic
CB1R activation is a suppression of neurotransmitter
release, whereby activation of presynaptic CB1Rs inhibits
action potential-evoked and spontaneous inhibitory post-
synaptic currents (IPSCs) at IN–PC synapses (see Fig. 1)
or excitatory postsynaptic currents (EPSCs) at PF–PC and
CF–PC synapses (Takahashi & Linden, 2000; Szabo et al.
2004; Kano et al. 2009).We have also usedmulti-electrode
array recording to demonstrate that CB1R ligand-induced
changes to cerebellar cortex network activity aremediated,
at least in part, via effects on inhibitory synaptic trans-
mission (Ma et al. 2008). CB1R activation has been
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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Figure 1. Presynaptic CB1Rmodulation of inhibitory transmission at IN–PC synapses is deficient in ataxic
ducky2J mice
Aa and Ba, representative spontaneous inhibitory postsynaptic current (sIPSC) traces from +/+ (Aa) and du2J/du2J
(Ba) PCs showing effect of WIN55 (5 μM), and also subsequent application of AM251 (2 μM). Ab and Bb,
summary bar graphs showing that WIN55 significantly reduced, and AM251 significantly increased, normalized
sIPSC frequency in +/+ (Ab), but was without effect in du2J/du2J (Bb), conditions. ∗P < 0.05; ∗∗P < 0.01;
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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widely associated with a number of different forms of
short- and long-term synaptic plasticities whichmodulate
cerebellar learning (Kano et al. 2009; Ohno-Shosaku &
Kano, 2014). Thus, 2-AG release mediates the short-term
suppression of inhibitory GABA release from IN terminals
(depolarization-induced suppression of inhibition) or
excitatory glutamate release (depolarization-induced
suppression of excitation) (Szabo et al. 2006; Tanimura
et al. 2009). Seminal work by Ito (1989) linked long term
depression (LTD) by associative stimulation of PF and CF
inputs to PCs, to motor learning in the cerebellum. It
is also known that the metabotropic glutamate receptor
1 (mGluR1) pathway is critically involved in cerebellar
development and LTD (Aiba et al. 1994), and it was further
proposed that CF inputs into individual PCswere required
for normal motor coordination (Chen et al. 1995). More
recent work has established that cerebellar LTD is a post-
synaptic phenomenon requiring 2-AG release from PCs
and activation of presynaptic CB1Rs at PF–PC synapses
(Safo & Regehr, 2005). Here, mGluR1 activation drives
2-AG release (Kano et al. 2009; see Abstract Figure). Thus,
CB1Rs have a privileged position in the function and
control of overall output of the cerebellar cortex and,
as such, represent good potential targets to modulate
dysfunctional signalling associated with cerebellar
ataxias.
In cell lines and native neurons, CB1R activation causes
pertussis toxin-sensitive inhibitionofCaV2 familyVDCCs,
and can also activate inwardly rectifier K+ channels
(Mackie & Hille, 1992; Twitchell et al. 1997; Guo & Ikeda,
2004). It is likely that CB1Rs couple to presynaptic CaV2.1
(P/Q-type) VDCCs at IN–PC synapses to reduce action
potential evoked GABA release (Forti et al. 2000; Stephens
et al. 2001; Lonchamp et al. 2009) and to CaV2.1 (and to
a lesser extent CaV2.2 and CaV2.3) at PF–PC synapses to
reduce action potential-evoked glutamate release (Brown
et al. 2004); these effects aremost likely mediated by direct
binding of G protein Gβγ subunits to VDCCs (Abstract
Figure and Fig. 1).
CB1R agonists also cause clear reductions in
frequency of ‘miniature’ IPSCs at IN–PC synapses
(Takahashi & Linden, 2000; Yamasaki et al. 2006;
Ma et al. 2008), consistent with an inhibition of
action potential-independent GABA release. These effects
are proposed to occur downstream of actions on
voltage-dependent ion channels and are also consistent
with direct effects on the synaptic release machinery,
and also may be mediated by Gβγ subunits (Stephens,
2009). By contrast, CB1R agonist effects on mini-
ature EPSCs at PF–PC synapses were only apparent
when extracellular Ca2+ levels were increased (Yamasaki
et al. 2006). Moreover, CB1R antagonists/inverse
agonists such as AM251, rimonabant and the pCB
9-tetrahydrocannabivarin all increase inhibitory GABA
release at IN–PC synapses (Ma et al. 2008). Such effects
are consistent with the presence of a strong, modulatable
eCB tone in the cerebellum (Kreitzer et al. 2002; Galante
& Diana, 2004), which provides further opportunity for
therapeutic intervention in cerebellar ataxia.
Importantly, activation of presynaptic CB1Rs by
synthetic cannabinoids and eCBs has been shown to
promote cerebellar dysfunction, causing severe motor
incoordination andmodelling cerebellar ataxia (Lichtman
et al. 1998; DeSanty & Dar, 2001; Patel & Hillard, 2001);
in these studies pre-treatment with a CB1R antagonist
or CB1R antisense prevented the induction of an ataxic
phenotype. Such data suggest that CB1R antagonism may
be useful in the pathogenic situation. In comparison
to administration of CB1R ligands, data with CB1R
knock-out mice are somewhat more equivocal. Thus,
young/mature CB1R deficient mice are reported not
to exhibit clear motor discoordination or changes to
gait (Steiner et al. 1999; Kishimoto & Kano, 2006);
however, deficits in motor function were reported in
mature and older mice, in comparison to unaffected
younger mice, in rotarod tests (Bilkei-Gorzo et al. 2005).
One interpretation of these studies is that a progressive
ataxic pathogenesis may be associated with long-term
loss of CB1R. One common feature of CB1R knock-out
mice, chronic marijuana users or animals administered
CB1R agonists is a reported deficit in delay eyeblink
conditioning, a cerebellar-dependent, motor learning
process (Kishimoto & Kano, 2006; Skosnik et al. 2008;
Steinmetz & Freeman, 2010). These data are consistent
withCB1R controlling discretemotor function.Kishimoto
& Kano (2006) also report that pharmacological block
of CB1R had no effect on motor function in wild-type
mice; however, it is also important to point out that
CB1R deficiency and/or lack of effect of CB1R antagonism
in a non-pathogenic situation does not preclude a role
repeatedmeasurement one-way ANOVA followed by Tukey’s honest significant difference test.Ac and Bc, summary
diagrams for +/+ (Ac) and du2J/du2J (Bc) conditions. Ad, in wild-type conditions, CB1R activation (i.e. +WIN55)
causes the release of Gβγ subunit from CB1R and subsequent inhibitory coupling of Gβγ to Cav2.1 at the
presynapse to inhibit the action potential-evoked GABA release seen in control (CTL). Bd, by contrast, in du2J/du2J
conditions, CB1R activation (i.e. +WIN55) has no effect on the GABA release seen in control (CTL). AM251 effects
were also absent (seeWang et al. 2013). Thus, we propose that at synapses lacking α2δ-2 subunits (which associate
predominantly with CaV2.1 in the cerebellum; Barclay et al. 2001), normal CB1R modulation of CaV2.1 is lacking.
This deficit may relate to incorrect control of synaptic release by α2δ subunits (Hoppa et al. 2012); alternatively, it
is possibly that lack of α2δ subunits may cause changes to CB1R-mediated G protein inhibition of CaV2.1.
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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in disease; for example, whilst SR141617A (rimonabant)
reversed CB1R-induced dysfunction, it had no effects
itself on motor incoordination in non-ataxic animals
(Lichtman et al. 1998; DeSanty & Dar, 2001). Together,
thesedata suggest thatCB1Rsmodulate cerebellar circuitry
in ataxic disease, potentially with a progressive onset of
effect. Therefore, targeting CB1Rs may be beneficial in
modulating motor incoordination in cerebellar ataxia, as
discussed more fully below.
An ataxic mouse model has deficient CB1R signalling
Whilst the role of ion channels (in particular, CaV2.1) has
been broadly studied in animal models of ataxia, there
has been much less work on the presynaptic receptors
that modulate neurotransmitter release and the post-
synaptic receptors responsible for onward signalling in
such models. A study in CaV2.1 mutant tottering mice by
Zhou and co-workers reported that presynaptic inhibition
mediated by GABAB or α2-adrenoceptor GPCRs was
enhanced at excitatory PF–PC synapses, although thismay
be as consequence of a switch to a reliance on CaV2.2
(N-type) channels for transmitter release (Zhou et al.
2003). Tottering mice also had a reduction in GABAA
receptor expression, with specific deficits in granule cells
(Kaja et al. 2007). We have shown that ataxic du2J
mutant mice exhibit increased irregularity of PC and,
to a lesser extent, granule cell firing in multi-electrode
array recordings from cerebellar brain slices (Wang et al.
2013). Of note, clear effects on PC firing regularity in
du2J/du2J mice were not seen in heterozygous +/du2J
mice, and the latter also lacked a clear behavioural ataxic
phenotype. Importantly, the CB1R-mediated inhibition
at IN–PC synapses seen in litter-matched controls was
completely absent in both +/du2J and du2J/du2J mice.
These data demonstrate that ataxic α2δ-2-deficient mice
have aberrant presynaptic CB1R-mediated signalling. The
question arises as towhether deficiency inCB1R-mediated
signalling is involved in ataxia pathogenesis or whether
it occurs as a result of the disease. It appears that, in
this model, both alleles need to be affected in order for
an ataxic phenotype to be seen (Wang et al. 2013), and
thus progressive deficits may be associated with du2J mice.
We saw no changes in PC firing regularity in response
to CB1R ligands in wild-type or du2J mice, consistent
with a lack of postsynaptic CB1R effects in this model.
We propose that such deficits occur due to compromised
Ca2+ channel activity consequent to reduced presynaptic
α2δ-2 expression in du2J mice (Fig. 1). In this regard,
α2δ-2 subunits have been shown to be essential not
only for Ca2+ channel trafficking (Dolphin, 2012), but
also for synaptic function, the latter by increasing trans-
mitter release probability and also protecting release from
inhibitory effects of intracellular Ca2+ chelators (Hoppa
et al. 2012).
There are few studies measuring CB1R expression in
ataxic animals; we reported no clear changes in expression
in the cerebellar cortex of +/du2J and du2J/du2J mice
(Wang et al. 2013). In a recent study, post-mortem
cerebellar tissue from patients with SCAs, CB1R (and
CB2R) expression was generally up-regulated in PCs, and
also in glial cells (Rodrı´guez-Cueto et al. 2014a). Of inter-
est here was that CB1R expression was reported in PC
soma and pinceau in SCA patients, but was confined
largely to the pinceau in control patients. It is possible
that upregulated postsynaptic CB1R expressionmay affect
2-AG release in SCA patients; however, Rodriguez-Cueto
and co-workers suggest that this CB1R expression is
associated with degenerating PCs and may represent a
marker for degeneration and/or a protective response
against such degeneration. A further study in SCApatients
reported an up-regulation of eCB degradative fatty acid
amide hydrolase and monoacylglycerol lipase (MAGL)
enzymes (Rodrı´guez-Cueto et al. 2014b), proposed to
lead to reduced eCB levels in disease. In these studies,
a compensatory up-regulation of cannabinoid receptor
expression may occur as a consequence of reduced eCB
levels; alternatively, it may be argued that eCBs are
suppressed in order not to overactivate the system. Thus, it
may also be possible to target eCB metabolizing enzymes
for future therapeutic development. In this regard,
potential avenues to increase 2-AG include inhibition
of MAGL, localized predominantly to the PF terminal
(Tanimura et al. 2012), or activation of the biosynthetic
enzyme diacylglycerol lipase-α (DAGLα) localized pre-
dominantly to the base of postsynaptic dendritic spines
(Yoshida et al. 2006) (see Abstract Figure). It is also clear
that we will need to investigate potential changes to eCB
signalling in different animal models of ataxia to inform
development of the most useful therapeutic strategies and
also to determine if any such changes represent useful
markers for different forms of ataxia.
Do cannabinoids have therapeutic utility in cerebellar
ataxia?
There are anecdotal reports that cannabis smokers can
achieve symptom relief for several CNS disorders. Such
evidence has fuelled the investigation of use of CB1R
agonists as potential neuroprotective agents for a range of
conditions including epilepsy, neurodegenerative diseases
such as Alzheimer’s, Parkinson’s andHuntington’s disease
and appetitive disorders (Ferna´ndez-Ruiz et al. 2011;
Hill et al. 2012a). Earlier evidence for ataxia is largely
confined to two case studies which suggest that oral
9-THC or marijuana improved motor coordination in
some multiple sclerosis patients (Clifford, 1983; Meinck
et al. 1989). At the clinical level, synthetic 9-THC has
been used inmanagement of nausea, emesis and pain, and
nabiximols (Sativex) (containing 1:1 9-THC:CBD)
C© 2016 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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represents the first phytocannabinoid medicine, used as
an oromucosal spray for pain and spasticity associated
with multiple sclerosis (Hill et al. 2012a); Sativex was
also stated to delay onset of ataxia symptoms in the
Medicines and Healthcare products Regulatory Agency
(MHRA) Public Information Report UK/H/961/01/DC.
Such reports contributed to fuelling a major review on
the clinical effects of cannabinoids in ataxia associated
with multiple sclerosis (Mills et al. 2007); although
cannabinoids showed promise, it was concluded that
better standardizedmeasures of ataxiawere needed to fully
establish the utility of cannabis-basedmedicines in ataxia.
The role of cannabinoids in disease-associated movement
disorders and tremor has been further discussed more
recently by Arjmand et al. (2015) and Kluger et al.
(2015), who similarly concluded that further work on
cannabinoids in different models of ataxia is warranted.
In this regard, an interesting recent report suggests that
a ‘Sativex-like’ combination of 9-THC and CBD, as
well as the individual administration of 9-THC or
CBD, was able to improve motor deficits in a viral
model of multiple sclerosis (Feliu´ et al. 2015). Clearly,
studies which suggest CB1R activation may be useful in
cerebellar ataxia contrast to preclinical data where CB1R
agonists induce an ataxic phenotype (Lichtman et al. 1998;
DeSanty & Dar, 2001; Patel & Hillard, 2001); however,
these data do support the hypothesis that maintaining
the correct balance in eCB system signalling is a major
factor for proper control of motor coordination. This
hypothesis is further supported by data from CaV2.1
mutants described above, where both decreases (Maejima
et al. 2013) and increases in Ca2+ current (Gao et al. 2012)
can produce an ataxia phenotype; moreover, deficits in
delay eyeblink conditioning are reported for both CB1R
agonists and CB1R antagonists/inverse agonists using the
same experimental design (Steinmetz & Freeman, 2010).
CB1R agonists have also been shown to possess functional
selectively or ‘biased agonism’, whereby different ligands
(including eCBs) preferentially activate different CB1R
signalling pathways (Laprairie et al. 2014; Khajehali et al.
2015). Whilst, as argued above, it is likely that CB1Rs
act predominantly on presynaptic CaV2.1 to reduce trans-
mitter release in the cerebellar cortex, alternative signalling
pathways include inhibition of cAMP or stimulation of
phosphorylation of signal regulated kinases (Howlett et al.
2010). Thus, it could be argued that by using knowledge
of biased agonism that we can target specific pathways
associated with diseases, including cerebellar ataxia.
Finallyhere,CB1Ragonists suchas9-THChave alsobeen
proposed to possess anti-oxidant (Hampson et al. 1998)
and anti-inflammatory (although largelyCB2R-mediated)
(Ferna´ndez-Ruiz et al. 2011) properties; in common with
other degenerative diseases, such properties may benefit
the amelioration of cerebellar ataxia symptoms.
The demonstration that pre-treatment with a
CB1R antagonist prevents the induction of motor
incoordination by CB1R agonists (DeSanty & Dar,
2001; Patel & Hillard, 2001) suggests that CB1R
antagonists/inverse agonists may be protective in ataxia.
The archetypal agent rimonabant was introduced
as an anti-obesity agent, but was withdrawn due
to fears of increased suicidality and depression in
patients (Nathan et al. 2011). Since then, therapeutic
development of CB1R antagonists/inverse agonists has
largely been put on hold. Interesting potential alternatives
are CB1R negative allosteric antagonists, such as
Org-27569 and PSNCBAM-1. These compounds have
a somewhat unique pharmacological profile as they
increase orthosteric agonist binding, but decrease agonist
activity; more intriguingly, allosteric antagonism action is
ligand-dependent and also shows biased antagonism for
different signalling pathways (Baillie et al. 2013). We have
shown that such functional selectivity for PSNCBAM-1
extends to effects on orthosteric ligands at IN–PC
synapses in the cerebellar cortex (Wang et al. 2011); thus,
PSNCBAM-1 attenuated CP55940 agonist and AM251
antagonist effects, but had no clear effects against WIN
55,212-2. Moreover, when applied alone, PSNCBAM-1
was not associated with potentially deleterious effects
on eCB tone, a concern associated with use of CB1R
antagonists/inverse agonists such as rimonabant. These
studies indicate that exogenous allosteric CB1R ligands
have potential to fine tune eCB orthosteric agonist effects
in a ligand- and/or cell signalling-selective manner within
the cerebellar cortex; moreover, biased antagonism effects
may allow for further useful therapeutic development.
This review has focused on cannabinoids as agents
acting on the eCB system in the cerebellum; moreover, the
modulation of CB1Rs has been highlighted. It may trans-
pire that, for exogenous compounds, targeting alternative
modes of action offers improved therapeutic potential
in diseases such as ataxia. The last few years have seen
increasing calls for the use of medical marijuana to
treat a range of disorders; of course, use of marijuana
is intimately associated with psychoactive effects of the
CB1R partial agonist 9-THC. Therapeutically, a more
attractive option may be use of non-psychoactive pCBs.
Thus, CBD and cannabidivarin (CBDV) have reported
utility in epilepsy and, potentially, other CNS disorders
(Hill et al. 2012b, 2013; Devinsky et al. 2014). The
demonstration that Sativex can improve motor activity
in multiple sclerosis (Feliu´ et al. 2015) is consistent
with beneficial effects of a CB1R activator (9-THC) in
combination with CBD as a potential ameliorating agent
for unwanted 9-THC effects (McPartland et al. 2015);
for example, CBD alone was also effective in improving
motor deficits, potentially via an action on peroxisome
proliferator-activated receptor γ (PPARγ) receptors (Feliu´
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et al. 2015). In this regard, CBD has recently been
awarded orphan drug status for the severe childhood
epilepsy Dravet syndrome and is currently progressing
well through clinical trials. CBD and CBDV have only low
affinity at CB1Rs and CBD has been proposed, amongst
other possibilities, to act at alternative GPCRs or at
transient receptor potential ion channels or, possibly, to
augment eCB tone via effects on metabolic enzymes (Hill
et al. 2012a; McPartland et al. 2015). A recent study has
proposed that CBD, as well as having CB1R-independent
actions, may also act as a CB1R negative allosteric
antagonist (Laprairie et al. 2015); therefore, CBD may
share useful properties of this class of agents discussed
above. It is also of interest that the hypophagic effects of
the allosteric antagonist Org27569 have been suggested
to occur independently of CB1Rs (Ding et al. 2014;
Gamage et al. 2014). Thus, the use of cannabinoids with
CB1R-independent and/or allosteric actions should also
be considered.
In the future, it will be of interest in particular to test
agents such as Sativex, and perhaps CBD as an individual
compound, in cerebellar ataxia. There are a number of
general points to consider, including whether deficits in
CB1R-mediated signalling are hallmark characteristics of
different forms of ataxia, how best to target such deficits
and whether aberrant cannabinergic signalling represents
a useful biomarker for early or asymptomatic cerebellar
ataxia. The answer to such questions will go some way
to determining if modulation of the eCB system has
therapeutic utility in cerebellar ataxia.
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